CC's Q2 loss narrows, but lower volumes and sales weigh on results as it outlines a cautious Q3 outl

Analysts update ratings on top stocks. View all changes, including upgrades and downgrades, on anal

UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price

 The products further expand the industry-leading Opteon™ portfolio and provide customers with addit

New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in st

CNC, DAR, GD, FCEL and CC stocks show how women-led companies are redefining growth with discipline,

Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after rece

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers th

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the

The Chemours Company (CC) Q2 2026 Earnings Call Transcript

Chemours NYSE: CC said its second-quarter results reflected pricing gains, operational improvements

The headline numbers for Chemours (CC) give insight into how the company performed in the quarter en

Chemours (CC) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estim

Chemours (NYSE:CC) widens FY2026 sales outlook from $5.982 billion-$6.098 billion to $5.866 billion-

Chemours (NYSE:CC) reported quarterly earnings of $0.42 per share which met the analyst consensus es

WILMINGTON, Del., Aug. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC) today an

WILMINGTON, Del., Aug. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (N

Shares of The Chemours Company (NYSE: CC - Get Free Report) have received an average rating of "Mode

Investors need to pay close attention to CC stock based on the movements in the options market latel

Chemours (CC) possesses the right combination of the two key ingredients for a likely earnings beat

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

A recovery in end-market demand and self-help measures, including cost cuts and productivity gains,

Fifth Third Bancorp increased its holdings in The Chemours Company (NYSE: CC) by 2,624.0% during the

Broker rating upgrades and robust earnings growth forecasts put PENN, CC and LITE in the spotlight a

WILMINGTON, Del., July 23, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (

Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of The Chemours Company (N

[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the add

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price t

Stockholm, July 1st, 2026 – Virtune today announces the completion of the rebalancing for the Virtun

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and raise

Analysts changed outlook on top names, RBC raised CC price target, DA Davidson lowered MSA target, O

Wall Street has rarely been louder with bubble warnings on the AI trade after the parabolic moves we

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and raises th

Memory is yesterday's trade. Liquid cooling is the next AI backlog story — Carrier orders up 500

Full Year 2026 Outlook The Company continues to expect 2026 Net Sales to grow in the range of 3% to

Second Quarter 2026 Outlook In the second quarter, the Company anticipates consolidated Net Sales to

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the

Dow Jones up 150 pts, Citi Trends $CTRN up 20.8% on strong earnings, other big gainers include Getty

BMO warns Middle East conflict is the biggest oil market event in decades. See how supply risks are

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price t

Goldman Sachs analyst Duffy Fischer maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Successful qualification of Opteon™ fluid in 2CRSi server sparks broader collaboration to drive inno

BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the pr

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the pr

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and raise